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Abstract    35 
We estimated the risk and probability of progression to osteopenia/osteoporosis by studying 36 
our HIV-infected patients who had at least 2 DXA scans (3,726 DXA scans from 875 37 
patients) (1999-2016). Time-nonhomogeneous bidirectional multistate models based on 3 38 
states (normal BMD, osteopenia, osteoporosis) were used to model the progression of 39 
BMD as a function of age and to study the association between the risk of bone loss and 40 
antiretroviral use. 41 
At the first DXA scan, 52.2% had osteopenia, and 16.7% osteoporosis. The hazard ratios 42 
associated with age (>45 vs. ≤45 years) for men and women were: 1) from normal BMD to 43 
osteopenia, 0.71 (95%-CI: 0.45-1.11) and 1.06 (95%-CI: 0.55-2.05), respectively; and 2) 44 
from osteopenia to osteoporosis, 0.83 (0.51-1.35) and 0.99 (0.38-2.56), respectively. The 45 
probability of transition from osteopenia to osteoporosis over 10 years among men aged 30, 46 
40, and 50 years was 14.9% (95% CI: 10.5-20.4%), 17.2% (14-21.3%), and 19% 14.3-47 
24.3%), respectively; for women, 6.9% (3.1-14.4%), 21.1% (14.8-29.5%), and 30.1% 48 
(19.8-41.8%), respectively. An increased risk of osteoporosis was observed for PIs and PIs 49 
plus TDF; darunavir was associated with a higher risk among men (HR: 3.9; 95% CI: 2-50 
7.5) and women (4.5; 1.4-14.7); atazanavir for women (HR: 4.2; 95% CI: 1.3-14). 51 
Our results highlight the importance of monitoring BMD owing to the high probability of 52 
progression to osteopenia/osteoporosis, even at early ages, especially in women. In the 53 
coming decade, changes in antiretrovirals other than tenofovir, such as PIs, should be 54 
recommended to reduce the risk of fracture. 55 
 56 
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INTRODUCTION 61 
HIV-infected people have a high risk of osteoporosis owing to multiple factors related not 62 
only to the host, but also to the virus, chronic inflammation, and antiretroviral treatment (1-63 
8). Evidence from large cohort studies points to a higher prevalence of low-energy fractures 64 
in HIV-infected persons than in the general population (5, 8-14). However, despite the 65 
many recently published recommendations on management of bone disease in HIV-infected 66 
individuals (15-19), the current low frequency of fracture managed in our daily clinical 67 
practice could make physicians less sensitive to evaluate bone health. Consequently, 68 
osteoporosis seems to be underdiagnosed and, consequently, undertreated in HIV-infected 69 
persons, thus leaving this population vulnerable to early fractures and disability (20). 70 
However, in aging persons, the long-term nature of HIV infection, persistent systemic 71 
inflammatory status, and prolonged exposure to antiretroviral drugs make the number of 72 
bone fractures among this population likely to increase. This is especially true in 73 
individuals aged 50 years or older (10,11). Therefore, clinicians should be aware of 74 
problems affecting bone and proactively manage bone health.  75 
 76 
In this study, we estimate the magnitude of an emerging problem among chronically HIV-77 
infected persons by studying progression to osteopenia/osteoporosis in a large cohort of 78 
patients assessed using dual-energy X-ray absorptiometry (DXA) scan. 79 
 80 
METHODS 81 
Study design, population, and objective 82 
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We performed a retrospective longitudinal observational study of all DXA scans from HIV-83 
infected patients attended in our HIV Unit and who had had at least 2 DXA scans between 84 
January 1999 and December 2016.  85 
The analysis included 3,726 DXA scans from 875 patients. The scans were requested as 86 
part of the patient’s follow-up in clinical practice or in the context of clinical trials. In 87 
recent years, DXA scans were requested according to current recommendations for HIV-88 
infected persons as follows: men aged >50 years, menopausal women, persons with a 89 
history of bone fractures, or patients using drugs or with diseases associated with a decrease 90 
in bone mineral density (BMD) (18,19). 91 
The main objective of the study was to evaluate the risk of progression of bone loss. 92 
Patients were classified into 3 groups according to their BMD: normal BMD, osteopenia, 93 
and osteoporosis. We estimated the following: 1) the percentage of patients in each group at 94 
the first and last DXA scan; 2) the number of transitions from one group to another (normal 95 
BMD to osteopenia, osteopenia to osteoporosis, or osteoporosis to osteopenia); 3) the risk 96 
of progression of bone loss or bone gain; 4) the probability of progression over time; and 5) 97 
the risk of low BMD according to the antiretroviral drugs used during the year before each 98 
DXA scan (tenofovir disoproxil fumarate [TDF], protease inhibitors [PI], combination of 99 
both [TDF and PI], and the use of lopinavir or atazanavir or darunavir).  100 
 101 
The T score for the lumbar spine (L1-L4) and hip (femoral neck, trochanter, and total 102 
femur) measured by DXA (Lunar Prodigy, GE Healthcare, Belgium) was collected, and the 103 
minimum of the four T scores was considered for patient’s classification. Osteopenia and 104 
osteoporosis were defined following the criteria of the World Health Organization (WHO), 105 
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as follows: normal BMD, minimum T score > –1.0 SD; osteopenia, minimum T score –1.0 106 
SD to –2.5 SD; and osteoporosis, minimum T score < –2.5 SD (21). 107 
 108 
Statistical analysis        109 
Categorical variables of interest were described using absolute and relative frequencies; 110 
numerical variables were described using the median and interquartile range (IQR).  111 
The BMD history was studied following a multistate model. The model assumes 3 states —112 
normal BMD (State 1), osteopenia (State 2), and osteoporosis (State 3)— and the time scale 113 
chosen is based on age at the DXA scan. The 4 possible transitions considered are 114 
transitions from State 1 to State 2 and from 2 to 3, corresponding to bone loss, and 115 
transitions from State 2 to State 1 and from 3 to 2, corresponding to bone recovery. Each of 116 
these 4 transitions can be characterized based on the instantaneous transition intensities 117 
(α12, α21, α23, α32) or, equivalently, on the transition probabilities. The model was fitted 118 
assuming that the future time course depends only on the present state and not on the 119 
previous history (Markov property). In addition, constant transition intensities were 120 
assumed before and after the age of 45 years; for example, in the case of the transition from 121 
State 1 to State 2,  = 
  if t ≤ 45 and   = 
	
 if t ≥ 45. The choice of this 122 
cutoff value was based on the data being 45 (years) the average midpoint of the age 123 
intervals from the first to the last DXA scan. Based on the estimates of the transition 124 
intensities, transition probabilities can be estimated as a function of age (22). This 125 
estimation was made first by using separate models without covariates for both women and 126 
men. Next, the use of antiretroviral drugs during the year prior to the DXA scan was 127 
included as a covariate in the model, in 4 different ways: PI vs. no PI; TDF vs. no TDF; 128 
combined use of PI and TDF; and specific PI (atazanavir, darunavir, lopinavir, or other). 129 
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The possible effects of these drugs were studied by transition-specific hazard regression 130 
models, which provide the hazard ratio as the effect size measure of interest.  131 
All statistical analyses were performed using R (R Foundation for Statistical Computing, 132 
Vienna, Austria), version 3.3.2, in particular, the msm package, which enables a multistate 133 
model to be fitted to panel data, that is, with observations of a continuous-time process at 134 
arbitrary times (23). 135 
 136 
RESULTS 137 
The analysis included 3,726 DXA scans from 875 patients who had had at least 2 DXA 138 
scans. During the 18 years of follow-up, the median number of scans per patient was 3 139 
(range: 2-18), the median time (IQR) from the first to the last DXA scan was 5 years (2.2-140 
9.6), and the median (IQR) time between consecutive DXA scans was 1.1 years (0.6-2.2). 141 
Among the 875 patients, 294 (33.6%) had 2 DXA scans, 188 (21.5%) had 3, 118 (13.5%) 142 
had 4, and 275 (31.4%) had 5 or more DXA scans. 143 
The median age (IQR) of the cohort at the first DXA scan was 41.7 (36.5-47.8) years, and 144 
75.3% were men. Epidemiological and clinical data at the time of the first DXA scan are 145 
summarized in Table 1. 146 
 147 
Prevalence and transitions 148 
The overall percentages of patients in the 3 groups at the first DXA scan were as follows: 149 
31.1% for normal BMD, 52.2% for osteopenia, and 16.7% for osteoporosis. At the last 150 
DXA these values were 28.1% for normal BMD, 54.5% for osteopenia, and 17.4% for 151 
osteoporosis. Figure 1A shows the joint distribution of the states at the first and the last 152 
DXA scan. 153 
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The total numbers of DXA scans among the 659 men and 216 women were 2828 and 898, 154 
respectively. Hence, there were 2169 transitions in subsequent DXA scans (2828-659) in 155 
men and 682 transitions (898-216) in women; the corresponding distributions are shown in 156 
Figures 1B and 1C. A deterioration in BMD from one DXA scan to the next was observed 157 
in 174 transitions (8%) among men (94 from normal BMD to osteopenia and 80 from 158 
osteopenia to osteoporosis) and in 75 transitions (11%) among women (46 from normal 159 
BMD to osteopenia and 29 from osteopenia to osteoporosis). An improvement was 160 
observed in 178 transitions (8.2%) and 37 transitions (5.4%), respectively.  161 
 162 
Risk of progression 163 
The risk of progression of bone loss or bone gain was studied as a function of age (>45 vs. 164 
≤45 years). The hazard ratios associated with age for HIV-infected patients were as 165 
follows: 1) transition from normal BMD to osteopenia, 0.71 (95% CI: 0.45-1.11) for men 166 
and 1.06 (95%-CI: 0.55-2.05) for women; 2) transition from osteopenia to osteoporosis, 167 
0.83 (0.51-1.35) for men and 0.99 (0.38-2.56) for women; 3) transition from osteopenia to 168 
normal BMD, 0.41 (0.26-0.65) for men and 0.42 (0.18-0.99) for women; and 4) transition 169 
from osteoporosis to osteopenia, 0.67 (0.42-1.05) for men and 0.12 (0.04-0.36) for women. 170 
Figure 2 shows the estimated hazard ratios associated with age for both genders. 171 
 172 
Probability of progression 173 
Figure 3A shows the estimated probabilities of progression from normal BMD to 174 
osteopenia/osteoporosis over 10 years among HIV-infected men and women aged 30, 40, 175 
and 50 years. Given a normal BMD at baseline, the probability that a 30-year-old HIV-176 
infected man progresses to either osteopenia or osteoporosis at age 40 is 60.6% (95% CI: 177 
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53.9-69.7%) and 51.1% (39-64.5%) for a 30-year-old woman. The corresponding 178 
probabilities of progression for men and women aged 40 to 50 years, respectively, are 179 
62.6% (55.8-70.5%) and 59.5% (50.1-70.1%), and for those aged 50 to 60 years, 59.7% 180 
(49.2-71.1%) and 62.4% (47.2-77.3%).  181 
With respect to the transition from osteopenia to osteoporosis, the estimated transition 182 
probabilities over 10 years are shown in Figure 3B. In HIV-infected men aged 30, 40, and 183 
50 years, the probabilities were 14.9% (95% CI: 10.5-20.4%), 17.2% (14-21.3%), and 19% 184 
(14.3-24.3%), respectively. A different probability pattern was obtained for women, with 185 
values of 6.9% (3.1-14.4%), 21.1% (14.8-29.5%), and 30.1% (19.8-41.8%), respectively.  186 
 187 
Risk of low BMD according to antiretroviral therapy   188 
Information on antiretroviral treatment regimens 1 year before the DXA scans was 189 
available for 862 of the 875 patients (98.5%), ie, 3516 of the 3726 DXA scans (94.4%) 190 
(Table 1). The estimated hazard ratios (HRs) associated with treatment combinations 191 
containing PI/TDF for both deterioration transitions are shown in Figures 4A (men) and 4B 192 
(women), respectively. In the cases of HIV-infected women, increased risks for 193 
osteoporosis were observed both for use of PIs versus no PI+no TDF (HR: 5.9; 95% CI: 194 
1.2-27.6) and for combined use of PIs plus TDF versus no PI+no TDF (HR: 6.9; 95% CI: 195 
1.4-34.4). The corresponding values among HIV-infected men were 1.8 (95% CI: 0.9-3.4) 196 
and 1.2 (95% CI: 0.6-2.6), respectively.  197 
Darunavir was associated with a higher risk of osteoporosis among men (HR: 3.9; 95% CI: 198 
2-7.5) and women (HR: 4.5; 95% CI: 1.4-14.7), as well as with a higher risk of osteopenia 199 
among women (HR: 2.8; 95% CI: 1.1-7.1) (Figures 5A and 5B). In addition, atazanavir 200 
increased the risk of osteoporosis among women (HR: 4.2; 95% CI: 1.3-14), although this 201 
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varied little among men (HR: 1.2; 95% CI: 0.4-3.2). The always larger confidence intervals 202 
among HIV-infected women result from the smaller sample size and the small number of 203 
transitions. 204 
A sensitivity analysis considering cutoff values other than 45 years (>40 vs. ≤40 years and 205 
>50 vs. ≤50 years) was carried out to ensure that the conclusions on the effects of the 206 
antiretroviral therapies did not depend on that choice. The models using different cutoffs 207 
provided nearly exactly the same estimates of the hazard ratios and confidence intervals of 208 
the hazard ratios associated with antiretroviral therapy (data not shown). 209 
 210 
 211 
Discussion  212 
The prevalence of osteopenia and osteoporosis was high in our cohort. The risk and the 213 
probability of progression from osteopenia to osteoporosis over 10 years were higher 214 
among women, especially those aged over 40 years; for men, the risk increased 215 
progressively, although the increment was more attenuated. Therapy with darunavir and 216 
atazanavir was associated with an increased risk of progression to bone loss. 217 
 218 
Osteoporosis is a major public health problem owing to the impact of osteoporotic bone 219 
fracture, whose health consequences include not only chronic pain, respiratory 220 
compromise, reduced mobility, disability, and mortality, but also increased social cost 221 
because of lost workdays, increased health and nursing care, and long-term rehabilitation. 222 
Consequently, assessment of the risk of fracture should be a high priority among health 223 
measures. Since the mid-1990s, the WHO operational definition of osteoporosis has been 224 
based on measurement of BMD using DXA in order to identify persons at higher risk of 225 
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bone fracture. It is well known that decreases in vertebral and hip BMD predict vertebral 226 
fractures (relative risk [RR]: 2.3; 95% CI. 1.9-2.8]) and hip fractures (RR: 2.6; 95% CI: 227 
2.0-3.5), respectively (24). 228 
 229 
The rate of osteoporosis appears to be greater in HIV-infected individuals than in the 230 
general population and is progressively increasing (6, 25, 26). In our cohort of almost 900 231 
persons, of whom 25% were women, only a third of the population had a normal BMD; 232 
half had osteopenia and 17% osteoporosis. These rates are similar to those observed in 233 
other cohorts (8,27) and support the relevance of this condition in HIV-infected persons.  234 
Nevertheless, osteoporotic fractures still remain very infrequent in daily clinical practice, 235 
and physicians rarely evaluate the risk of fractures. We wanted to assess the magnitude of 236 
this problem in the near future by determining the risk and likelihood of progression to 237 
osteoporosis in 10 years in a large cohort of chronically HIV-infected persons assessed 238 
using DXA scan, with a median of 3 scans per patient (more than 60% had 3 or more scans) 239 
and a median of 5 years from the first to the last DXA scan. 240 
First, in order to obtain an overview of progression of bone loss in the DXA scans, we 241 
analyzed transitions from one DXA scan to the next. Deterioration of BMD —defined as a 242 
change in status from normal BMD to osteopenia or from osteopenia to osteoporosis 243 
between 2 consecutive DXA scans— was observed in around 10% of transitions; this rate 244 
was considerably high, considering that the median time between consecutive DXA scans 245 
was only 1 year. Improvement was observed in 5-8% of transitions, and the difference was 246 
similar in men and women.  247 
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When the risk of progression was calculated according to age (>45 vs. ≤45 years, >40 vs. 248 
≤40 years and >50 vs. ≤50 years) and gender, the risk of bone loss changed little with age. 249 
The low number of patients aged 60 or over included in the study could make it difficult to 250 
detect differences in deterioration between age groups. On the other hand, as expected, the 251 
risk of recovery (bone gain) was more likely for patients younger than 45 years. This 252 
finding supports the assessment of bone health at early ages and suggests that intensive 253 
interventions should be implemented, if necessary, at early stages of bone loss to achieve 254 
better recovery. 255 
However, when we evaluated the probability of progression over time, it is noteworthy that 256 
the probability of progression from normal BMD to osteopenia/osteoporosis over 10 years 257 
was very high, around 50-60%, and similar between men and women and for persons aged 258 
30, 40, or 50 years. In other words, at the age of 30 years, the probability of progression to 259 
osteopenia was as high as 60.6% for men and 51.1% for women at 10 years. In contrast, 260 
when we evaluated the probability of progression from osteopenia to osteoporosis, larger 261 
differences between age and gender were obtained; the estimated risks of progression were 262 
14.9%, 17.2%, and 19% for men at age 30, 40, and 50 years, respectively, and 6.9%, 263 
21.1%, and 30.1% for women. These data indicate that with respect to a 30-year-old 264 
woman, the risk of progressing to osteoporosis is 3-fold higher in a 40-year-old woman, 265 
and almost 5-fold higher in a 50-year-old woman, whereas in a man, the risk of progression 266 
is much lower. Data assessing the BMD decline over time according to the HIV status have 267 
been recently published with controversial results (25,26). Unfortunately, our study cannot 268 
elucidate this question because HIV-uninfected controls were not included.  269 
  270 
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As for antiretroviral therapy, besides evidence for TDF, there is solid evidence about the 271 
potential negative effect of PIs on BMD (5,6,27,28). In Japanese HIV-infected patients, the 272 
duration of treatment with a PI correlated significantly with bone loss, while 273 
discontinuation of the PI enabled bone recovery, especially in the lumbar spine (27). 274 
However, data from other studies did not found association between BMD decline and the 275 
use of PIs (25,26). Our results confirm the impact of PIs on bone loss, which was notable 276 
among women taking PIs and PIs+TDF. In men, a trend towards the risk of osteoporosis 277 
was seen with the use of PIs; however, it is unknown whether this is a class effect of all PIs 278 
or whether it is an adverse effect of a specific PI. To our knowledge, there are no firm data 279 
about the specific role of each individual PI in bone loss. Our large sample size made it 280 
possible to evaluate the individual impact of the most commonly used PIs (atazanavir, 281 
lopinavir, and darunavir). Having a closer look at the specific PIs, darunavir was associated 282 
with risk of bone loss among men and women, whereas atazanavir was only associated with 283 
this risk in women. These results, together with data from studies in which the PI is 284 
replaced or interrupted (27,29), support the recommendation to avoid or change PIs, if 285 
possible, in the case of osteoporosis (18). However, this finding should be interpreted with 286 
caution because only the antiretroviral combination received during the year before the 287 
DXA scan was analyzed. The retrospective nature of the study prevents us from evaluating 288 
the cumulative and continuous effect of each antiretroviral agent. In addition, the effect of 289 
other secondary risk factors on bone loss, such as menopausia, or the use of treatment for 290 
osteoporosis on bone gain was not assessed. 291 
 292 
In conclusion, given the increased prevalence of osteoporosis and risk of bone fractures in 293 
HIV-infected individuals, osteoporosis and other factors leading to fracture, such as 294 
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sarcopenia, should be regularly assessed in clinical practice. DXA scan or fracture 295 
prediction algorithms such as the FRAX® equation (30) help to identify individuals at risk. 296 
Our results highlight the need for monitoring of BMD owing to the high probability of 297 
progression to osteopenia, even at early ages, in both genders, and to osteoporosis, 298 
especially in women aged ≥40 years. In addition, changes in antiretroviral drugs other than 299 
tenofovir (eg, PIs), changes in lifestyle, and non-pharmacological and pharmacological 300 
interventions should be recommended to reduce the risk of recurrence of fracture in the 301 
coming decade among individuals at high risk. 302 
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 385 
Table 1.  Epidemiological and clinical data at the first DXA scan. 386 
 875 patients 
Gender, men, n (%) 659 (75.3%) 
Age, years  41.7 (36.1-47.8) 
DXA scans per patient, number 3 (2-18) 
Patients and DXA scans, n (%) 
      Two DXA scans 
      Three DXA scans 
      Four DXA scans 






Time from the first to the last DXA scan, years 5 (2.2-9.6) 
Time between consecutive DXA scans, years  1.1 (0.6-2.2) 
Antiretroviral therapy during the year before DXA, number  
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of DXA scans (%) * 
      PI + TDF 
      Only PI 
      Only TDF 






DXA scans in patients receiving a PI, n (%)  
      Darunavir 
      Lopinavir  
      Atazanavir 






Values are expressed as median (IQR) or number (%). 387 
PI, protease inhibitor; TDF, tenofovir disoproxil fumarate. 388 
*Information on the antiretroviral treatment regimens 1 year before the DXA scans was 389 
available for 862 of the 875 patients (98.5%), i , 3516 of the 3726 DXA scans (94.4%). 390 
391 
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Figure 1A. 393 
 394 
 395 
Figure 1B.  396 
 397 
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Figure 1C. 399 
 400 
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Figure Legends  434 
Figure 1A: Joint distribution of the BMD status at the first and last DXA scans. 435 
Figure 1B: Total number of transitions among men. 436 
Figure 1C: Total number of transitions among women. 437 
Figure 2: Estimated hazard ratios and 95% confidence intervals associated with age (>45 438 
years vs. ≤45 years) for model transitions. Lines in black indicate a greater likelihood of 439 
recovery from bone loss among younger HIV-infected patients. 440 
Figure 3A: Estimated probabilities of transition from normal bone mineral density to 441 
osteopenia/osteoporosis over 10 years for HIV-infected patients aged 30, 40, and 50 years. 442 
Figure 3B: Estimated probabilities of transition from osteopenia to osteoporosis over 10 443 
years for HIV-infected patients aged 30, 40, and 50 years. 444 
Figure 4A: Estimated hazard ratios and 95% confidence intervals associated with PIs and 445 
TDF in monotherapy and combined among HIV-infected men. Left panel: Transition from 446 
normal bone mineral density to osteopenia; right panel: transition from osteopenia to 447 
osteoporosis. 448 
Figure 4B: Estimated hazard ratios and 95% confidence intervals associated with PIs and 449 
TDF in monotherapy and combined among HIV-infected women. Left panel: transition 450 
from normal bone mineral density to osteopenia; right panel: transition from osteopenia to 451 
osteoporosis. 452 
Figure 5A: Estimated hazard ratios and 95% confidence intervals associated with specific 453 
PIs among HIV-infected men. Left panel: transition from normal bone mineral density to 454 
osteopenia; right panel: transition from osteopenia to osteoporosis. 455 
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Figure 5B: Estimated hazard ratios and 95% confidence intervals associated with specific 456 
PIs among HIV-infected women. Left panel: Transition from normal bone mineral density 457 
to osteopenia; right panel: transition from osteopenia to osteoporosis. 458 
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